- Author: Alexandra C Cheerva, MD, MS; Chief Editor: Hassan M Yaish, MD more...
The combination of giant hemangioma, thrombocytopenia, and consumptive coagulopathy is termed Kasabach-Merritt syndrome (KMS). KMS is an infrequent but potentially fatal complication of rapidly growing vascular lesions in infants. See the image below.
Signs and symptoms
Signs and symptoms in KMS include the following:
Visible cutaneous giant hemangioma or multiple smaller hemangiomas, usually on the extremities
Hepatomegaly or jaundice
Petechiae, bruising, and frank bleeding
Physical findings may include the following:
Cutaneous hemangioma, often appearing as a large irregular bruise anywhere on the body and often circumscribed by widespread, overlying, shiny and dusky, purple skin
Kaposiform hemangioendothelioma (KHE) or tufted angioma (TA) - Blue or reddish-brown discoloration and skin induration
Petechiae and bruising
Painful, tender lesions
Bleeding from thrombocytopenia and coagulopathy (locally and, at times, distantly [disseminated intravascular coagulation (DIC)])
Tachycardia, feeding difficulty, and shock (signs of high-output cardiac failure)
Pallor (suggestive of anemia)
See Presentation for more detail.
Any infant with unexplained thrombocytopenia, with or without evidence of DIC, should be evaluated for visceral or hidden vascular lesions (especially of the liver or spleen).
Laboratory studies that may be helpful include the following:
Complete blood count (CBC) count with differential, reticulocyte count, platelet count, and peripheral smear examination
Prothrombin time (PT) and activated partial thromboplastin time (aPTT) - These are prolonged in patients with significant DIC
Fibrinogen, fibrin degradation product (FDP), and D-dimer levels - The first are reduced in DIC, and the second and third are elevated
Blood culture (to exclude sepsis)
Chromosome tests (to exclude certain genetic syndromes)
Diagnostic imaging is obtained as appropriate and may include the following:
Computed tomography (CT)
Magnetic resonance imaging (MRI)
Doppler flow studies
Although formal staging is not usually performed, documenting the extent of the invasion of the hemangioma into normal tissue is important for possible subsequent treatment with surgery or radiation. Hemangiomas do not metastasize.
See Workup for more detail.
No single pharmacologic therapy has been proved most effective in patients with KMS. Agents that have been tried (most of them not specifically FDA-approved for this application), with varying success, include the following:
Corticosteroids (most commonly used)
Aminocaproic acid (to treat bleeding)
Vincristine (80% response reported)
Propranolol (unlike in infantile hemangioma, response is poor)
Nonpharmacologic treatment modalities include the following:
Surgical resection (when lesions are not too large or surgically inaccessible) - Wide local excision is recommended but may be difficult; amputation may be necessary for intractable lesions involving a limb
Interventional radiologic procedures (when surgical treatment is not feasible)
Intermittent pneumatic compression (most useful for a vascular lesion located on an extremity)
Radiation therapy (now largely abandoned because of long-term adverse effects)
The Kasabach-Merritt syndrome (KMS) was first described in 1940 in a male infant with a large, rapidly enlarging discolored lesion on his thigh that was associated with consumptive coagulopathy and thrombocytopenia. The lesion in this original case was a kaposiform hemangioendothelioma, not a classic infantile hemangioma. The combination of enlarging vascular lesion (either a kaposiform hemangioendothelioma or a tufted angioma), profound thrombocytopenia, microangiopathic hemolytic anemia, and consumptive coagulopathy is termed KMS or Kasabach-Merritt phenomenon (KMP).[1, 2]
The vascular lesion may be an obvious superficial lesion or a lesion within a visceral organ or even within the brain. Thrombocytopenia is often severe (ie, platelet count < 50,000/µL). Thrombocytopenia and consumptive coagulopathy are not complications of all vascular lesions, and size alone does not determine which vascular lesions are associated with thrombocytopenia and coagulopathies. KMS is infrequent but has a potentially fatal outcome (reported at 40% in one report) and is characterized by rapid growth of the vascular lesions in infants. Infantile hemangiomas, the most common tumors of infancy, typically undergo rapid postnatal growth for several months, followed by a prolonged phase of involution.
Pathophysiology and Etiology
The thrombocytopenia associated with vascular lesions is caused by a localized consumptive coagulopathy. The vascular lesion triggers an intravascular coagulation with platelet trapping, consequent thrombocytopenia, and fibrinogen consumption and degradation, as well as activation and consumption of coagulation factors, resulting in disseminated intravascular coagulation (DIC). Activation of platelets also promotes further growth of vascular tissue.
KMS is associated with the two following rare vascular lesions::
The phenomenon may be associated with trauma in the area of the vascular lesion.
United States and international statistics
Hemangiomas are common vascular tumors that occur in as many as 2.5% of neonates in the United States. Most are benign, and 70-80% regress by the age of 7 years. Some hemangiomas are life-threatening; 1 hemangioma in 300 is associated with coagulopathy. Worldwide, reports of KMS are rare.
Age-, sex-, and race-related demographics
KMS typically occurs in early infancy (< 1 year) or childhood, though prenatal cases (diagnosed with the aid of ultrasonography), newborn presentations, and rare cases in older children and adults have been reported. KMS should be included in the differential diagnosis of unexplained chronic thrombocytopenia at any age.
Boys and men are affected slightly more often than girls and women are. In this respect, KMS differs notably from hemangioma of infancy (infantile hemangioma), which affects girls much more often than it does boys. No racial predilection has been identified.
When KMS is promptly recognized and properly treated, the prognosis is usually excellent because the DIC resolves as the vascular lesion recedes and because KMS does not recur. Therefore, most children do well if they reach age 2 years. When KMS goes untreated, mortality is 10-37%, primarily due to bleeding secondary to the consumptive coagulopathy. Even after failed treatment, however, the hematologic abnormalities may spontaneously resolve over a few months.
Mortality and morbidity are influenced by the anatomic location, depth, and extent of the vascular lesion. Besides bleeding, other conditions associated with morbidity and mortality are as follows:
Visceral involvement (particularly in the retroperitoneal area and mediastinum)
Iatrogenic complications (eg, from procedures such as arterial ligation, arterial embolization, or surgical excision)
Hemolytic anemia resulting from physical damage to the red blood cells (RBCs) may be mild, moderate, or severe. The results of the direct antibody test (DAT) or the Coombs test is negative in patients with anemia, and anemia is secondary to microangiopathic destruction of the RBCs, manifested by the presence of schistocytes on peripheral blood smear examination (a helpful tool in suggesting the presence of viseral hemangiomas).
Heart failure often occurs in affected infants as a result of the large volume of blood flowing through the giant hemangioma.
An association of KMS with trisomy 21 mosaicism is uncommon; however, 43% of children with Down syndrome have cutaneous vascular lesions. One child with Down syndrome and KMS has been reported.
Kasabach HH, Merritt KK. Capillary hemangioma with extensive purpura: report of a case. Am J Dis Child. 1940. 59:1063-70.
Kelly M. Kasabach-Merritt phenomenon. Pediatr Clin North Am. 2010 Oct. 57(5):1085-9. [Medline].
Hatley RM, Sabio H, Howell CG, Flickinger F, Parrish RA. Successful management of an infant with a giant hemangioma of the retroperitoneum and Kasabach-Merritt syndrome with alpha-interferon. J Pediatr Surg. 1993 Oct. 28(10):1356-7; discussion 1358-9. [Medline].
Martin MC, Harrington H, Wong WW. Massive congenital kaposiform hemangioendothelioma of the eyelid in a neonate. J Craniofac Surg. 2011 Nov. 22(6):e38-41. [Medline].
Enjolras O, Wassef M, Mazoyer E, et al. Infants with Kasabach-Merritt syndrome do not have "true" hemangiomas. J Pediatr. 1997 Apr. 130(4):631-40. [Medline].
Szlachetka DM. Kasabach-Merritt syndrome: a case review. Neonatal Netw. 1998 Feb. 17(1):7-15. [Medline].
Payne LG, Hayward CPM, Kelton JG. Destruction of red cells by the vasculature and reticuloendothelial system. Hematology of Infancy and Childhood. 1998. 523-43.
Berman B, Lim H. Concurrent cutaneous and hepatic hemangiomata in infancy: report of a case and a review of the literature. J Dermatol Surg Oncol. 1978 Nov. 4(11):869-73. [Medline].
Ram SP. Kasabach-Merritt syndrome and Down's syndrome. J R Soc Med. 1997 Mar. 90(3):159-60. [Medline].
Enjolras O, Riche MC, Merland JJ, Escande JP. Management of alarming hemangiomas in infancy: a review of 25 cases. Pediatrics. 1990 Apr. 85(4):491-8. [Medline].
Tang JY, Chen J, Pan C, Yin MZ, Zhu M. Diffuse cavernous hemangioma of the spleen with Kasabach-Merritt syndrome misdiagnosed as idiopathic thrombocytopenia in a child. World J Pediatr. 2008 Aug. 4(3):227-30. [Medline].
Mitsuhashi N, Furuta M, Sakurai H, et al. Outcome of radiation therapy for patients with Kasabach-Merritt syndrome. Int J Radiat Oncol Biol Phys. 1997 Sep 1. 39(2):467-73. [Medline].
Pampin C, Devillers A, Treguier C, et al. Intratumoral consumption of indium-111-labeled platelets in a child with splenic hemangioma and thrombocytopenia. J Pediatr Hematol Oncol. 2000 May-Jun. 22(3):256-8. [Medline].
Sadan N, Wolach B. Treatment of hemangiomas of infants with high doses of prednisone. J Pediatr. 1996 Jan. 128(1):141-6. [Medline].
Nako Y, Fukushima N, Igarashi T, Hoshino M, Sugiyama M, Tomomasa T, et al. Successful interferon therapy in a neonate with life-threatening Kasabach-Merritt syndrome. J Perinatol. 1997 May-Jun. 17(3):244-7. [Medline].
Hu B, Lachman R, Phillips J, et al. Kasabach-Merritt syndrome-associated kaposiform hemangioendothelioma successfully treated with cyclophosphamide, vincristine, and actinomycin D. J Pediatr Hematol Oncol. 1998 Nov-Dec. 20(6):567-9. [Medline].
Wananukul S, Nuchprayoon I, Seksarn P. Treatment of Kasabach-Merritt syndrome: a stepwise regimen of prednisolone, dipyridamole, and interferon. Int J Dermatol. 2003 Sep. 42(9):741-8. [Medline].
Drucker AM, Pope E, Mahant S, Weinstein M. Vincristine and corticosteroids as first-line treatment of Kasabach-Merritt syndrome in kaposiform hemangioendothelioma. J Cutan Med Surg. 2009 May-Jun. 13(3):155-9. [Medline].
López V, Martí N, Pereda C, Martín JM, Ramón D, Mayordomo E, et al. Successful management of Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon using vincristine and ticlopidine. Pediatr Dermatol. 2009 May-Jun. 26(3):365-6. [Medline].
Hara K, Yoshida T, Kajiume T, Ohno N, Kawaguchi H, Kobayashi M. Successful treatment of Kasabach-Merritt syndrome with vincristine and diagnosis of the hemangioma using three-dimensional imaging. Pediatr Hematol Oncol. 2009 Jul-Aug. 26(5):375-80. [Medline].
Hartman KR, Moncur JT, Minniti CP, Creamer KM. Mediastinal Kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon in an infant: treatment with interferon. J Pediatr Hematol Oncol. 2009 Sep. 31(9):690-2. [Medline].
Yoon HS, Lee JH, Moon HN, Seo JJ, Im HJ, Goo HW. Successful treatment of retroperitoneal infantile hemangioendothelioma with Kasabach-Merritt syndrome using steroid, alpha-interferon, and vincristine. J Pediatr Hematol Oncol. 2009 Dec. 31(12):952-4. [Medline].
Blei F, Karp N, Rofsky N, Rosen R, Greco MA. Successful multimodal therapy for kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon: case report and review of the literature. Pediatr Hematol Oncol. 1998 Jul-Aug. 15(4):295-305. [Medline].
Leong E, Bydder S. Use of radiotherapy to treat life-threatening Kasabach-Merritt syndrome. J Med Imaging Radiat Oncol. 2009 Feb. 53(1):87-91. [Medline].
Argenta LC, Bishop E, Cho KJ, et al. Complete resolution of life-threatening hemangioma by embolization and corticosteroids. Plast Reconstr Surg. 1982 Dec. 70(6):739-44. [Medline].
Stanley P, Gomperts E, Woolley MM. Kasabach-Merritt syndrome treated by therapeutic embolization with polyvinyl alcohol. Am J Pediatr Hematol Oncol. 1986 Winter. 8(4):308-11. [Medline].
Jiang RS, Hu R. Successful treatment of Kasabach-Merritt syndrome arising from kaposiform hemangioendothelioma by systemic corticosteroid therapy and surgery. Int J Clin Oncol. 2012 Oct. 17(5):512-6. [Medline].
Akyuz C, Emir S, Buyukpamukcu M, et al. Successful treatment with interferon alfa in infiltrating angiolipoma: a case presenting with Kasabach-Merritt syndrome. Arch Dis Child. 2003 Jan. 88(1):67-8. [Medline]. [Full Text].
Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med. 1992 May 28. 326(22):1456-63. [Medline].
Michaud AP, Bauman NM, Burke DK, et al. Spastic diplegia and other motor disturbances in infants receiving interferon-alpha. Laryngoscope. 2004 Jul. 114(7):1231-6. [Medline].
de la Hunt MN. Kasabach-Merritt syndrome: dangers of interferon and successful treatment with pentoxifylline. J Pediatr Surg. 2006 Jan. 41(1):e29-31. [Medline].
Haisley-Royster C, Enjolras O, Frieden IJ, et al. Kasabach-merritt phenomenon: a retrospective study of treatment with vincristine. J Pediatr Hematol Oncol. 2002 Aug-Sep. 24(6):459-62. [Medline].
Hurvitz SA, Hurvitz CH, Sloninsky L, Sanford MC. Successful treatment with cyclophosphamide of life-threatening diffuse hemangiomatosis involving the liver. J Pediatr Hematol Oncol. 2000 Nov-Dec. 22(6):527-32. [Medline].
Perez Payarols J, Pardo Masferrer J, Gomez Bellvert C. Treatment of life-threatening infantile hemangiomas with vincristine. N Engl J Med. 1995 Jul 6. 333(1):69. [Medline].
Fernandez-Pineda I, Lopez-Gutierrez JC, Ramirez G, Marquez C. Vincristine-ticlopidine-aspirin: an effective therapy in children with Kasabach-Merritt phenomenon associated with vascular tumors. Pediatr Hematol Oncol. 2010 Nov. 27(8):641-5. [Medline].
Traivaree C, Lumkul R, Torcharus K, Krutuecho T, Sriphaisal T. Outcome of Kasabach-Merritt phenomenon: the role of vincristine as monotherapy: report of a case. J Med Assoc Thai. 2012 May. 95 Suppl 5:S181-5. [Medline].
Fuchimoto Y, Morikawa N, Kuroda T, Hirobe S, Kamagata S, Kumagai M, et al. Vincristine, actinomycin D, cyclophosphamide chemotherapy resolves Kasabach-Merritt syndrome resistant to conventional therapies. Pediatr Int. 2012 Apr. 54(2):285-7. [Medline].
Leaute-Labreze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taieb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008 Jun 12. 358(24):2649-51. [Medline].
Su L, Wang D, Fan X. Comprehensive therapy for hemangioma presenting with Kasabach-Merritt syndrome in the maxillofacial region. J Oral Maxillofac Surg. 2015 Jan. 73 (1):92-8. [Medline].
George M, Singhal V, Sharma V, Nopper AJ. Successful surgical excision of a complex vascular lesion in an infant with Kasabach-Merritt syndrome. Pediatr Dermatol. 2002 Jul-Aug. 19(4):340-4. [Medline].
Yang YH, Lee PI, Lin KH, Tsang YM. Absolute ethanol embolotherapy for hemangioma with Kasabach-Merritt syndrome. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1998 Jan-Feb. 39(1):51-4. [Medline].
Hosono S, Ohno T, Kimoto H, Nagoshi R, Shimizu M, Nozawa M, et al. Successful transcutaneous arterial embolization of a giant hemangioma associated with high-output cardiac failure and Kasabach-Merritt syndrome in a neonate: a case report. J Perinat Med. 1999. 27(5):399-403. [Medline].
Komiyama M, Nakajima H, Kitano S, Sakamoto H, Kurimasa H, Ozaki H. Endovascular treatment of huge cervicofacial hemangioma complicated by Kasabach-Merritt syndrome. Pediatr Neurosurg. 2000 Jul. 33(1):26-30. [Medline].
Wolfe SQ, Farhat H, Elhammady MS, Moftakhar R, Aziz-Sultan MA. Transarterial embolization of a scalp hemangioma presenting with Kasabach-Merritt syndrome. J Neurosurg Pediatr. 2009 Nov. 4(5):453-7. [Medline].
Enomoto Y, Yoshimura S, Egashira Y, Iwama T. Transarterial embolization for cervical hemangioma associated with Kasabach-merritt syndrome. Neurol Med Chir (Tokyo). 2011. 51(5):375-8. [Medline].
Poetke M, Philipp C, Berlien HP. Flashlamp-pumped pulsed dye laser for hemangiomas in infancy: treatment of superficial vs mixed hemangiomas. Arch Dermatol. 2000 May. 136(5):628-32. [Medline].
Aylett SE, Williams AF, Bevan DH, Holmes SJ. The Kasabach-Merritt syndrome: treatment with intermittent pneumatic compression. Arch Dis Child. 1990 Jul. 65(7):790-1. [Medline].
Schild SE, Buskirk SJ, Frick LM, Cupps RE. Radiotherapy for large symptomatic hemangiomas. Int J Radiat Oncol Biol Phys. 1991 Aug. 21(3):729-35. [Medline].
Hesselmann S, Micke O, Marquardt T, et al. Case report: Kasabach-Merritt syndrome: a review of the therapeutic options and a case report of successful treatment with radiotherapy and interferon alpha. Br J Radiol. 2002 Feb. 75(890):180-4. [Medline].